- Home
- PROK vs GBLI Comparison
PROK vs GBLI Comparison
Compare PROK & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PROK | GBLI |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.1M | 395.4M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | PROK | GBLI |
|---|---|---|
| Price | $1.79 | $26.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.40 | N/A |
| AVG Volume (30 Days) | ★ 996.7K | 4.3K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 5.13% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.29 |
| Revenue | $893,000.00 | ★ $450,098,000.00 |
| Revenue This Year | N/A | $14.23 |
| Revenue Next Year | N/A | $9.68 |
| P/E Ratio | ★ N/A | $93.10 |
| Revenue Growth | ★ 1075.00 | 2.02 |
| 52 Week Low | $0.54 | $25.63 |
| 52 Week High | $7.13 | $34.00 |
Technical Indicators
Market Signals| Indicator | PROK | GBLI |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 43.69 |
| Support Level | $1.73 | $25.76 |
| Resistance Level | $2.58 | $28.78 |
| Average True Range (ATR) | 0.13 | 0.35 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 59.30 | 16.21 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.